Literature DB >> 16306527

Antioxidant therapy for idiopathic pulmonary fibrosis.

Gary W Hunninghake.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 16306527     DOI： 10.1056/NEJMe058210

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  21 in total

Review 1.  Idiopathic pulmonary fibrosis : new concepts in pathogenesis and implications for drug therapy.

Authors:  Jeffrey C Horowitz; Victor J Thannickal
Journal:  Treat Respir Med       Date:  2006

2.  Peroxiredoxin II expression and its association with oxidative stress and cell proliferation in human idiopathic pulmonary fibrosis.

Authors:  Kirsi Vuorinen; Steffen Ohlmeier; Outi Leppäranta; Kaisa Salmenkivi; Marjukka Myllärniemi; Vuokko L Kinnula
Journal:  J Histochem Cytochem       Date:  2008-07-07       Impact factor: 2.479

3.  An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management.

Authors:  Ganesh Raghu; Harold R Collard; Jim J Egan; Fernando J Martinez; Juergen Behr; Kevin K Brown; Thomas V Colby; Jean-François Cordier; Kevin R Flaherty; Joseph A Lasky; David A Lynch; Jay H Ryu; Jeffrey J Swigris; Athol U Wells; Julio Ancochea; Demosthenes Bouros; Carlos Carvalho; Ulrich Costabel; Masahito Ebina; David M Hansell; Takeshi Johkoh; Dong Soon Kim; Talmadge E King; Yasuhiro Kondoh; Jeffrey Myers; Nestor L Müller; Andrew G Nicholson; Luca Richeldi; Moisés Selman; Rosalind F Dudden; Barbara S Griss; Shandra L Protzko; Holger J Schünemann
Journal:  Am J Respir Crit Care Med       Date:  2011-03-15       Impact factor: 21.405

Review 4.  Epithelial-mesenchymal interactions in pulmonary fibrosis.

Authors:  Jeffrey C Horowitz; Victor J Thannickal
Journal:  Semin Respir Crit Care Med       Date:  2006-12       Impact factor: 3.119

5.  Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis.

Authors:  Ganesh Raghu; Kevin J Anstrom; Talmadge E King; Joseph A Lasky; Fernando J Martinez
Journal:  N Engl J Med       Date:  2012-05-20       Impact factor: 91.245

6.  Therapeutic value of small molecule inhibitor to plasminogen activator inhibitor-1 for lung fibrosis.

Authors:  Wen-Tan Huang; Praveen K Vayalil; Toshio Miyata; James Hagood; Rui-Ming Liu
Journal:  Am J Respir Cell Mol Biol       Date:  2012-01       Impact factor: 6.914

7.  Analysis of blood neutrophil elastase, glutathione levels and pathological findings in postoperative acute exacerbation of idiopathic pulmonary fibrosis associated with lung cancer: Two case reports.

Authors:  Keishi Sugino; Yasuhiko Nakamura; Yoko Muramatsu; Yoshinobu Hata; Kazutoshi Shibuya; Sakae Homma
Journal:  Mol Clin Oncol       Date:  2016-08-12

Review 8.  New therapeutic targets in idiopathic pulmonary fibrosis. Aiming to rein in runaway wound-healing responses.

Authors:  Neil Ahluwalia; Barry S Shea; Andrew M Tager
Journal:  Am J Respir Crit Care Med       Date:  2014-10-15       Impact factor: 21.405

9.  Lung function in idiopathic pulmonary fibrosis--extended analyses of the IFIGENIA trial.

Authors:  Jürgen Behr; Maurits Demedts; Roland Buhl; Ulrich Costabel; Richard P N Dekhuijzen; Henk M Jansen; William MacNee; Michiel Thomeer; Benoit Wallaert; Francois Laurent; Andrew G Nicholson; Eric K Verbeken; Johny Verschakelen; C D R Flower; Stefano Petruzzelli; Paul De Vuyst; J M M van den Bosch; Eulogio Rodriguez-Becerra; Ida Lankhorst; Marco Sardina; Gabrielle Boissard
Journal:  Respir Res       Date:  2009-10-27

10.  S-nitrosothiols signal hypoxia-mimetic vascular pathology.

Authors:  Lisa A Palmer; Allan Doctor; Preeti Chhabra; Mary Lynn Sheram; Victor E Laubach; Molly Z Karlinsey; Michael S Forbes; Timothy Macdonald; Benjamin Gaston
Journal:  J Clin Invest       Date:  2007-09       Impact factor: 14.808
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.